The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors
| Autor: | Masaaki Takahashi, Naoya Okumura, Yuichi Kudaka, Kazuhide Banno, Tsuguhiro Kaneda, Atsushi Hirano |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Cyclopropanes
Efavirenz medicine.medical_treatment Pharmaceutical Science HIV Infections Pharmacology High-performance liquid chromatography chemistry.chemical_compound Pharmacokinetics medicine HIV Protease Inhibitor Humans Protease inhibitor (pharmacology) Darunavir Chromatography High Pressure Liquid Sulfonamides Protease Chromatography medicine.diagnostic_test Reproducibility of Results General Medicine HIV Protease Inhibitors Reference Standards Benzoxazines Solutions chemistry Therapeutic drug monitoring Alkynes Calibration HIV-1 Drug Monitoring medicine.drug |
| Zdroj: | Biologicalpharmaceutical bulletin. 30(10) |
| ISSN: | 0918-6158 |
| Popis: | Darunavir (DRV) is a new protease inhibitor used to treat human immunodeficiency virus (HIV) type-1. The aim of this study was to validate the determination of plasma DRV concentrations using the HPLC method, a simple procedure for simultaneous determination of seven HIV protease inhibitors and efavirenz. The calibration curve was linear (range of 0.13 to 10.36 microg/ml). The average accuracy ranged from 100.7 to 105.6%. Both the interday and intraday coefficients of variation were less than 6.7%, which was similar to or much lower than previously reported values by the LC/MS/MS method. It is concluded that HPLC can be used to determine plasma DRV concentrations and routinely in the clinical setting; thus, this HPLC method enables further study of DRV pharmacokinetics in conventional hospital laboratories. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|